Biomedicines and Acceleron Pharma. She joins Scholar Rock’s Executive Team, reporting directly to Jay Backstrom, M.D., MPH, President and Chief Executive Officer. As the Company transitions to a ...

Scholar Rock has done well to advance its anti-myostatin ... who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would ...

February is Heart Month, a time to focus on the health and well-being of Ontarians. In recognition of this, and in advance of the upcoming provincial election, we are calling on all political parties ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and Company ("Lilly"). This collaboration focuses on ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, has appointed Lisa Wyman as the Chief Technical and ...

Ms. Wyman brings more than 20 years of leadership and functional experience in technical and quality operations, including executive team responsibilities in her most recent roles at ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...